Dr. Steven Coca discusses the product of RenalytixAI called KidneyIntelX, a diagnostic solution that uses artificial intelligence to assess the combination of predictive blood-based biomarkers and other genomic information, in combination with electronic health record information, to create a powerful model for the prediction of disease progression and drug/therapy response in individual patients at risk for CKD.
Dr. Steven Coca, Associate Professor, Medicine, Nephrology; Associate Chair for Clinical and Translational Research for the Department of Internal Medicine, Mount Sinai Health System, and Co-Founder of RenalytixAI – a developer of artificial intelligence-enabled clinical diagnostic solutions for kidney disease, one of the most common and costly chronic medical conditions globally. Dr. Coca is a former graduate from University of New England College of Osteopathic Medicine. He completed his medical residency and clinical nephrology fellowship at Yale University and Yale New Haven Hospital in CT. He also received a Master’s Degree in Epidemiology and Public Health during his training at Yale. He was on faculty in the Section of Nephrology for 5 years as an Assistant Professor. Currently, he is an Associate Professor of Medicine at Icahn School of Medicine at Mount Sinai. His major research areas include using newer biomarkers to aide risk-stratification for outcomes in acute kidney injury and chronic kidney disease. His major clinical interests include AKI, CKD, electrolyte disorders, hypertension, and cardiorenal syndrome.